| 2024/07/16 13:33:11 | |
|---|---|
| Price | |
| 0.242 EUR | |
| Difference | 0.62% (0.00) |
General attributes
| ISIN | BE0974260896 |
| Symbol | CYAD |
| Exchange | Stuttgart |
| Currency | EUR |
| Sector | Chemical / Pharmaceutical / Health |
| Security type | Stock |
| Market cap (m) | 11 EUR |
| Benchmark | BEL 20 INDEX |
Market data
| Bid (Bid size) | - (0) |
| Ask (Ask size) | - (0) |
| Open | 0.24 EUR |
| High | 0.242 EUR |
| Low | 0.24 EUR |
| Close (prev. day) | 0.2405 EUR |
| VWAP | - |
| Volume (pcs) | 0 |
| Trading volume | 0.00 |
| Number of trades | 4 |
| Last size | 0 |
Futures and Options
| Related Futures | - |
| Related Options | - |
PDF Downloads
| Company report: CELYAD ONCOLOGY SA |  |
Scale: ABS REL
Instrument
Add Benchmark:
Information about previous performance does not guarantee future performance.Source: FactSet
Recent research
| Date | Headline | Download | |
| 2024/07/12 |
|
Global Equity Ratings |
|
| 2024/06/21 |
|
Global Equity Ratings |
|
| 2024/06/14 |
|
Global Equity Ratings |
|
| 2024/05/29 |
|
Global Equity Ratings |
|
| 2024/04/26 |
|
Global Equity Ratings |
|
| 2024/07/16 13:33:11 | |
|---|---|
| Price | |
| 0.242 EUR | |
| Difference | 0.62% (0.00) |
General attributes
| ISIN | BE0974260896 |
| Symbol | CYAD |
| Exchange | Stuttgart |
| Currency | EUR |
| Sector | Chemical / Pharmaceutical / Health |
| Security type | Stock |
| Market cap (m) | 11 EUR |
| Benchmark | BEL 20 INDEX |
Market data
| Bid (Bid size) | - (0) |
| Ask (Ask size) | - (0) |
| Open | 0.24 EUR |
| High | 0.242 EUR |
| Low | 0.24 EUR |
| Close (prev. day) | 0.2405 EUR |
| VWAP | - |
| Volume (pcs) | 0 |
| Trading volume | 0.00 |
| Number of trades | 4 |
| Last size | 0 |
Performance and Risk
| 6m | 1Y | 3Y | |
| Perf (%) | -27.54% | -53.28% | -93.14% |
| Perf (abs.) | -0.09 | -0.28 | -3.29 |
| Beta | 0.42 | 0.28 | 0.59 |
| Volatility | 78.82 | 107.76 | 108.59 |
Scale: ABS REL
Instrument
Add Benchmark:
Information about previous performance does not guarantee future performance.Source: FactSet
Price data
| Ø price 5 days | Ø volume 5 days (pcs.) | 0.244 EUR (0) |
| Ø price 30 days | Ø volume 30 days (pcs.) | 0.265 EUR (0) |
| Ø price 100 days | Ø volume 100 days (pcs.) | 0.299 EUR (0) |
| Ø price 250 days | Ø volume 250 days (pcs.) | 0.416 EUR (24) |
| YTD High | date | 0.416 EUR (2024/03/04) |
| YTD Low | date | 0.240 EUR (2024/07/11) |
| 52 Weeks High | date | 1.070 EUR (2023/09/04) |
| 52 Weeks Low | date | 0.240 EUR (2024/07/11) |
All listings for CELYAD ONCOLOGY SA
| Exchange | Date | Time | Price | Trading volume (mio.) | Number of trades |
| Berlin | 2024/07/16 | 08:08 | 0.2285 EUR | 0.00 | 3 |
| Duesseldorf | 2024/07/16 | 08:10 | 0.239 EUR | 0.00 | 3 |
| Euronext Brussels | 2024/07/16 | 17:35 | 0.2675 EUR | 0.00 | 20 |
| FINRA other OTC Issues | 2024/07/08 | 18:39 | 0.25 USD | 0.00 | 1 |
| Frankfurt | 2024/07/16 | 08:02 | 0.2285 EUR | 0.00 | 2 |
| London Stock Exchange | 2021/01/27 | 09:06 | 6.9303 EUR | 0.00 | 1 |
| Munich | 2024/07/16 | 08:08 | 0.299 EUR | 0.00 | 1 |
| Stuttgart | 2024/07/16 | 13:33 | 0.242 EUR | 0.00 | 4 |
Company Logo
Contact Details
| CELYAD ONCOLOGY SA |
| - - |
| Axis Business Park, Rue André Dumont 9 - 1435 Mont-Saint-Guibert |
| Telefon: +32-10-039-41-00 |
| Fax: +32-10-039-41-41 |
| E-mail: info@celyad.com |
PDF Downloads
| Company report: CELYAD ONCOLOGY SA | |
Company Profile
Celyad Oncology SA is a clinical-stage biotechnology company, which focuses on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer. It operates through the following segments: Cardiology and Immuno-Oncology. The Cardiology segment includes the company's Cardiopoiesis, Corquest, and C-Cathez platforms. The Immuno-Oncology segment consists of all assets developed based on the CAR-T cell platform. The company was founded by Michel Lussier, William Wijns, and Christian Homsy on July 24, 2007 and is headquartered in Mont-Saint-Guibert, Belgium. |
Members of Management Board
| Georges Rawadi | Chairman of Managing Board |
| An Phan | Member of Executive Committee |
| David Georges | Member of Executive Committee |
| Eytan Breman | Member of Executive Committee |
| Hannes Iserentant | Member of Executive Committee |
Board of directors
| Hilde Windels | Chairman of Supervisory Board |
| Marina Udier | Member of Supervisory Board |
| Ami Shah | Member of Supervisory Board |
| Andrea Gothing | Member of Supervisory Board |
| Dominic Piscitelli | Member of Supervisory Board |
| John LiPuma | Member of Supervisory Board |
| Jonathan James | Member of Supervisory Board |
| Sage Mandel | Member of Supervisory Board |
| Serge Goblet | Member of Supervisory Board |